Skip to content

Efficacy and safety evaluation for local anesthetics adds vertebral body infiltration anesthesia for PVP, PKP

Efficacy and safety evaluation for local anesthetics adds vertebral body infiltration anesthesia for PVP, PKP

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-15007363
Enrollment
Unknown
Registered
2015-11-09
Start date
2015-11-11
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporotic vertebral compression fracture

Interventions

The experimental group A.:5% lidocaine 1 ml
The experimental group B.:5% lidocaine 2 ml
The experimental group C.:none

Sponsors

The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
55 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. In accordance with the primary osteoporosis diagnosis standard and Chinese osteoporosis recommended diagnostic criteria, vertebral compression fractures caused by osteoporosis, Pain symptoms after conservative treatment 4 weeks still cannot alleviate or to prevent the may cause complications of long-term bed; 2. Aged from 55 to 80; 3. Sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Do not accord with standard of primary osteoporosis diagnosis; 2. Age less than 55 years old or older than 80 years old; 3. Vertebral compression degree of more than 75%; 4. Coagulant function abnormality; 5. The later period of malformation, disability, loss of labor; 6. Allergic constitution, and for a variety of drug allergy; 7. The cardiovascular system, respiratory system, central nervous system, liver, kidney, hematopoietic system, endocrine system function obviously abnormal; 8. Severe hypertension (SBP>=180mmHg, DBP>=110mmHg); 9. Can't tolerate surgery; 10. Is preparing or to attend other clinical trials.

Design outcomes

Primary

MeasureTime frame
cortisol;beta-endorplhin;Adrenaline;Adrenocorticotropic hormone;

Countries

China

Contacts

Public ContactZhang shuncong
drzsc@sina.com+86 13602765101

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026